A detailed history of Vanguard Group Inc transactions in Exagen Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 490,944 shares of XGN stock, worth $2.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
490,944
Previous 490,944 -0.0%
Holding current value
$2.53 Million
Previous $893,000 69.88%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$2.1 - $3.4 $350 - $567
167 Added 0.03%
490,944 $1.18 Million
Q2 2022

Aug 12, 2022

SELL
$4.18 - $7.74 $193,784 - $358,826
-46,360 Reduced 8.63%
490,777 $2.82 Million
Q1 2022

May 13, 2022

SELL
$7.12 - $11.06 $21,075 - $32,737
-2,960 Reduced 0.55%
537,137 $4.31 Million
Q4 2021

Feb 14, 2022

BUY
$8.97 - $14.08 $268,131 - $420,879
29,892 Added 5.86%
540,097 $6.28 Million
Q3 2021

Nov 12, 2021

SELL
$10.25 - $15.21 $99,097 - $147,050
-9,668 Reduced 1.86%
510,205 $6.94 Million
Q2 2021

Aug 13, 2021

BUY
$12.4 - $17.92 $6.45 Million - $9.32 Million
519,873 New
519,873 $7.79 Million

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $83.7M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.